Drugs / Vociprotafib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04916236 | Mar 2022 → Jul 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03634982 | Sep 2018 → Mar 2023 | cancer | Revolution Medicines, Inc. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04418661 | Jun 2020 → Apr 2024 | metastatic neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT03989115 | Jul 2019 → Feb 2022 | cancer | Revolution Medicines, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05054725 | Dec 2021 → Jul 2024 | non-small cell lung carcinoma | Revolution Medicines, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2022-08-07 | Amgen | Results AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS amgen.com ↗
First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation |
| 2021-08-11 | Revolution Medicines, Inc. | Results Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress revmed.com ↗
However, insufficient clinical benefit was observed to justify advancing this approach, and no additional patients will be enrolled in this study. |
| 2020-10-24 | Revolution Medicines, Inc. | Results Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers revmed.com ↗
Interim results suggest that a dual intermittent dosing strategy for RMC-4630 and cobimetinib exceeds target plasma exposures for each drug based on preclinical models of RAS pathway-driven cancers that project potential clinical activity. |
| 2020-06-22 | Revolution Medicines, Inc. | Results Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies revmed.com ↗
Expanded experience of anti-tumor activity in non-small cell lung cancer patients carrying KRAS mutations |
| 2020-01-13 | Revolution Medicines, Inc. | Results Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference revmed.com ↗
In this study RMC-4630 has shown reasonable tolerability and preliminary signs of clinical activity in patients with non-small cell lung cancer (NSCLC) harboring KRAS mutations, particularly KRASG12C. |
All press releases naming this drug 14 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vociprotafib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04418661 ↗ |
| Known as | Ptpn11 inhibitor rmc-4630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | RMC-0694630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | RMC-4630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03989115 ↗ |
| Known as | SAR-442720 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | SAR442729 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Action | Inhibit | “* SHP2-inhibitor” NCT04916236 ↗ |
| Modality | Small molecule | — CHEMBL5314427 ↗ |
| Route | Oral | “RMC-4630 for oral administration” NCT03634982 ↗ |
| Target | PTPN11 | “inhibition of SHP2 (also known as PTPN11)” PMID 29808006 ↗ May 2018 |